Join Sherly Mosessian, Ph.D., SOFIE’s Chief Scientific Officer, as she presents “Clinical Development Progress of FAP Targeting Radioligands”
Dr. Mosessian earned her bachelors degree in Biochemistry, followed by her Ph.D. from the UCLA Department of Molecular and Medical Pharmacology, with publications in tumor signaling, molecular imaging targets and clinical trials of Position Emission Tomography (PET) probes. In her role as SOFIE’s Chief Scientific Officer, she formulates the strategic plan for scientific objectives of the organization, including leading the FAPI clinical development program.
Date: Wednesday, May 13, 2026
Time: 3:30pm – 4:30pm EDT
In this session, Dr. Mosessian will help you to:
- describe the significance and potential of FAP as a target
- highlight recent developments in clinical trials with FAP targeting in imaging
- highlight recent developments in clinical trials with FAP targeting in therapy
- describe supply chain considerations to support future commercial launch
THIS ACTIVITY IS APPROVED FOR 1.0 CEH CREDIT BY SNMMI
Also, don’t miss our SNMMI Symposium FAP in Focus – Oncology and Horizons Beyond Cancer at the upcoming SNMMI Annual meeting. LEARN MORE >